ABL1 and ataxia telangiectasia: For the remaining patients, analysis for one (16.7%) patient revealed an ATM (ataxia telangiectasia) variant, targetable with Olaparib, Rucaparib, and Niraparib (e.g., BCL2 and pro-apoptotic pathway mechanisms), and an ABL1 variant, targetable with Bosutinib, Dasatinib, Imatinib, Nilotinib, and/or Ponatinib (e.g., BCR-ABL kinase pathway mechanisms).